Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Next Previous
Trial Profile

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Landipirdine (Primary)
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors Biotie Therapies Corp.

    • Most Recent Events

    • 01 Sep 2023 Results assessing safety, tolerability, and efficacy of SYN120 in patients with Parkinson disease dementia (PDD) published in the Parkinsonism and Related Disorders
    • 09 Oct 2018 Results assessing impact of Landipirdine on psychiatric symptoms, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 09 Oct 2018 Primary endpoint has not been met. (Change in Cognitive Drug Research Computerized Cognition Battery (CDR) Continuity of Attention from baseline)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top